使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and welcome to the Acadia Healthcare Second Quarter 2023 Earnings Conference Call.
各位好,歡迎參加 Acadia Healthcare 2023 年第二季財報電話會議。
(Operator Instructions)
(接線員指示)
Please note this event is being recorded. I would now like to turn the conference over to Gretchen Hommrich. Please go ahead.
請注意,本活動將進行錄音。我現在想將會議交給 Gretchen Hommrich。請開始。
Gretchen Hommrich - VP of IR
Gretchen Hommrich - VP of IR
Good morning, and welcome to Acadia's Second Quarter 2023 Conference Call. I'm Gretchen Hommrich, Vice President of Investor Relations for Acadia. I'll first provide you with our safe harbor before turning the call over to our Chief Executive Officer, Chris Hunter.
各位早安,歡迎參加 Acadia 2023 年第二季電話會議。我是 Gretchen Hommrich,Acadia 投資人關係副總裁。我將先提供我們的安全港聲明,之後把電話交給我們的執行長 Chris Hunter。
To the extent any non-GAAP financial measure is discussed in today's call. You will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link. This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2023 and beyond.
若今日電話會議中討論任何非 GAAP 財務衡量指標,您也可透過我們網站上的「投資人」連結,查看昨日新聞稿,以取得該指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。本次電話會議可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述,其中包括但不限於關於 Acadia 對 2023 年及其後預期之季度與年度財務表現的陳述。
You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's second quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements.
特此提醒您,這些陳述可能會受到多項重要因素影響(其中包括 Acadia 向美國證券交易委員會提交之文件以及公司第二季新聞稿中所載因素)。因此,實際營運與結果可能與前瞻性陳述中討論的結果存在重大差異。
At this time, I would like to turn the conference call over to our Chief Executive Officer, Chris Hunter, for opening remarks.
此時,我想將電話會議交給我們的執行長 Chris Hunter 發表開場致詞。
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Thank you, Gretchen, and good morning, everyone. Thank you for being with us for Acadia's Second Quarter 2023 Conference Call. For the second quarter, we reported impressive results across multiple measures. Given this momentum and our confidence in the continued strong performance of our business, we're increasing our guidance for the year. I'm eager to discuss our performance, but first, I want to acknowledge several outstanding additions to our leadership team. This includes Heather Dixon, who started with the company earlier this month as our new Chief Financial Officer. Heather brings significant executive-level financial expertise with substantial payer, provider and pharmacy experience across the health care landscape.
謝謝你,Gretchen,各位早安。感謝各位參加 Acadia 2023 年第二季電話會議。第二季我們在多項指標上都繳出亮眼成果。基於這股動能以及我們對業務持續強勁表現的信心,我們上調了全年財測。我很期待與各位討論我們的表現,但首先,我想提及我們領導團隊幾位傑出的新成員。其中包括 Heather Dixon,她於本月稍早加入公司,擔任新任財務長。Heather 具備豐富的高階財務專業,並在整體醫療照護領域擁有涵蓋付款方、醫療服務提供者與藥局的深厚經驗。
We're also pleased to welcome Judith Scimone, as the company's new Chief Human Resources Officer; and Brian Farley, is our Executive Vice President, General Counsel and Secretary. Both Judith and Brian bring deep experience and we know they will make valuable contributions in their respective roles. And as we welcome these new leaders, I want to also thank David Duckworth and Chris Howard for the contributions they made in support of Acadia's growth and success, we wish them the very best.
我們也很高興歡迎 Judith Scimone 擔任公司新任人力資源長;以及 Brian Farley 擔任執行副總裁、總法律顧問兼公司秘書。Judith 與 Brian 皆具備深厚經驗,我們相信他們將在各自職務上做出重要貢獻。在迎接這些新領導者之際,我也要感謝 David Duckworth 與 Chris Howard 對 Acadia 成長與成功所做的貢獻,並祝福他們一切順利。
Turning to the quarter. Our second quarter results reflect continued momentum in our business through the first half of 2023. Excluding $8.6 million of income from the provider relief fund recognized back in the second quarter of 2022, we reported year-over-year revenue growth of 12.2%, adjusted EBITDA growth of 10.9% and adjusted EPS growth of 9.5%. We are pleased with the growth trajectory of our business with solid performance across all service lines. Same facility revenue increased 11.4% compared with the same period last year. Notably, we achieved strong patient day growth of 4.9% and revenue per day growth of 6.1%, which is supported by favorable rate increases across our service lines, including CTC, markets and payers.
回到本季表現。我們第二季的結果反映出 2023 年上半年業務動能持續。排除 2022 年第二季認列之提供者紓困基金(provider relief fund)收入 860 萬美元後,我們的營收年增 12.2%、調整後 EBITDA 年增 10.9%、調整後每股盈餘(adjusted EPS)年增 9.5%。我們對業務的成長軌跡感到滿意,各服務線均有穩健表現。同院(same facility)營收較去年同期成長 11.4%。值得注意的是,我們達成強勁的病人日(patient day)成長 4.9% 與每日營收(revenue per day)成長 6.1%;此表現受惠於各服務線的有利費率調升,包括 CTC、各市場與付款方。
In line with our forecast, we continued to see sequential improvement in our labor trends with wage inflation decreasing from 7.5% in the first quarter of 2023 to 6.3% in the second quarter of 2023. While not all markets are the same, on an overall basis, the labor environment continues to show signs of improvement, positioning the company for continued stability in wage growth moderation over the remainder of the year. The team has continued to execute on our 5 distinct growth pathways with significant progress made this year.
符合我們的預期,我們的勞動力趨勢持續呈現逐季改善,薪資通膨由 2023 年第一季的 7.5% 降至 2023 年第二季的 6.3%。雖然各市場情況不盡相同,但整體而言,勞動環境持續出現改善跡象,使公司在今年剩餘期間能維持薪資成長放緩的穩定性。團隊也持續推進我們 5 條明確的成長路徑,且今年已取得顯著進展。
For our first pathway facility expansions, we added 98 beds to existing facilities in the second quarter, bringing the total additions to 204 beds to date. We expect to add a total of approximately 300 beds in 2023, consists to prior years. For our second pathway, we're making good progress towards our plan of accelerating wholly-owned de novo hospital growth. We're on schedule to open a newly renovated 101-bed adult hospital and outpatient facility, which is part of the Montrose Behavioral Health hospital in Chicago, Illinois as well as an 80-bed inpatient hospital, Coachella Valley Behavioral Health in Indio, California. Both are expected to commence operations later this year. And are actively -- we are actively identifying and advancing additional de novo expansion opportunities to open in 2024 and beyond.
在第一條成長路徑—既有設施擴建方面,我們於第二季在既有設施新增 98 張病床,使今年迄今新增總數達 204 張。我們預期 2023 年合計新增約 300 張病床,與過往年度一致。第二條路徑方面,我們在加速自建(wholly-owned)新設(de novo)醫院成長的計畫上進展良好。我們按計畫將於今年稍晚啟用位於伊利諾州芝加哥、隸屬於 Montrose Behavioral Health hospital 的全新整修 101 床成人醫院與門診設施,以及位於加州印第奧(Indio)的 80 床住院醫院 Coachella Valley Behavioral Health。兩者預計都將於今年稍晚開始營運。我們也正積極辨識並推進更多新設擴張機會,目標於 2024 年及之後開業。
Our network of CTCs also continues to expand, and we opened 2 new CTC locations in the second quarter. We're experiencing solid demand for medication-assisted treatment for patients dealing with opioid use disorder, a chronic disease affecting nearly 10 million individuals nationwide, that untreated can lead to serious potential consequences, including disability, relapse and death. We are focused on accelerating the expansion of our network of 153 CTCs in 32 states with the goal of adding at least 6 CTCs in 2023.
我們的 CTC 網絡也持續擴張,並於第二季新開設 2 個 CTC 據點。我們觀察到對藥物輔助治療(medication-assisted treatment)的穩健需求,服務對象為受阿片類藥物使用障礙(opioid use disorder)影響的患者;這是一種慢性疾病,全美約影響近 1,000 萬人,若未治療可能導致嚴重後果,包括失能、復發與死亡。我們聚焦於加速擴張目前遍及 32 州、共 153 家 CTC 的網絡,目標在 2023 年至少新增 6 家 CTC。
Regarding our third growth way, we are extremely proud of our work across the country with our joint venture partners, and we continue to expand this strategic network. We recently announced our 19th and 20th joint ventures, a partnership with Solution Health for a 144-bed behavioral health hospital in Southeast New Hampshire, as well as a partnership with Nebraska Methodist Health System for developing a 96 bed hospital that will serve the Omaha, Nebraska and Council Bluff, Iowa metropolitan area. These new hospitals will expand our acute service line into 2 additional states, New Hampshire and Iowa.
關於第三條成長路徑,我們對與全國各地合資(joint venture)夥伴的合作成果深感自豪,並持續擴大此策略性網絡。我們近期宣布第 19 與第 20 個合資案:與 Solution Health 合作,在新罕布夏州東南部興建一所 144 床的行為健康醫院;以及與 Nebraska Methodist Health System 合作,開發一所 96 床醫院,服務內布拉斯加州奧馬哈(Omaha)與愛荷華州康瑟爾布拉夫斯(Council Bluff)都會區。這些新醫院將把我們的急性照護服務線拓展至另外兩個州:新罕布夏州與愛荷華州。
As we have demonstrated in our other joint ventures, we will combine our expertise with the experience and established market presence of these leading providers to develop and provide quality behavioral health care services in their respective communities. Additionally, early in the third quarter, we opened a 96 bed hospital with our joint venture partner, Bronson Healthcare in Battle Creek, Michigan and another 96 bed hospital with our partner, Geisinger Behavioral Health Center Northeast in Moosic, Pennsylvania. We look forward to working together with these premier health systems to provide needed quality behavioral health care in their respective markets.
如同我們在其他合資案中所展現的,我們將結合自身專業與這些領先醫療服務提供者的經驗及既有市場能見度,在其各自社區開發並提供高品質的行為健康照護服務。此外,在第三季初,我們與合資夥伴 Bronson Healthcare 於密西根州巴特爾克里克(Battle Creek)開設了一所 96 床醫院,並與夥伴 Geisinger Behavioral Health Center Northeast 於賓夕法尼亞州穆西克(Moosic)開設另一所 96 床醫院。我們期待與這些頂尖醫療體系攜手合作,在各自市場提供所需的高品質行為健康照護。
Today, Acadia's 20 JV partnerships represent a combined total of 21 hospitals with 11 hospitals already in operation and 10 hospitals expected to open over the next several years. We have a growing pipeline of potential joint venture partners, and we'll continue to pursue this important growth pathway in '23 and beyond. For our fourth pathway, we continue to look for acquisitions that advance our growth strategy. We're excited about our announcement yesterday to acquire Turning Point Centers, a 76-bed specialty provider of substance use disorder, in primary mental health treatment services that serves the Salt Lake City, Utah metropolitan market. Turning Point Centers provides a full continuum of treatment services, including residential, partial hospitalization and intensive outpatient services. This acquisition will extend Acadia's geographic footprint for our specialty service line into a new state and enhance our continuum of care in Utah to include all 4 service lines. We expect to close this transaction in 2023.
目前,Acadia 的 20 個合資(JV)合作夥伴關係合計涵蓋 21 家醫院,其中 11 家已投入營運,另有 10 家預計在未來數年內開業。我們也有持續成長的潛在合資夥伴管線,並將在 2023 年及其後持續推進這項重要成長路徑。第四條路徑方面,我們持續尋找能推動成長策略的併購機會。我們對昨日宣布收購 Turning Point Centers 感到振奮;該公司為一家具 76 床的專科服務提供者,提供物質使用障礙(substance use disorder)與主要心理健康治療服務,服務範圍涵蓋猶他州鹽湖城都會市場。Turning Point Centers 提供完整的治療連續體(full continuum),包括住宿式(residential)、部分住院(partial hospitalization)與密集門診(intensive outpatient)服務。此收購將把 Acadia 的專科服務線地理版圖拓展至新州,並強化我們在猶他州的照護連續體,納入全部 4 條服務線。我們預期於 2023 年完成此交易交割。
Our fifth and final pathway is focused on improving our service offerings and ensuring that we have the appropriate level of care for patients seeking treatment. During the second quarter, we have expanded our treatment options by adding 14 outpatient programs in PHP IOPs and virtual services and 23 PHP IOPs since the beginning of the year at select facilities to assist patients after they leave inpatient and residential treatment. Through each of these 5 growth pathways, we are well positioned to maintain our strong growth trajectory and meet our stated development targets for calendar 2023 as follows: adding approximately 670 beds through approximately 300 bed additions to existing facilities, of which, we've already opened 204 year-to-date, opening 2 inpatient de novo hospitals, opening 2 hospitals with JV partners, which we completed early in the third quarter and opening at least 6 CTC locations, including the 2 already mentioned.
第五條也是最後一條成長路徑,聚焦於提升我們的服務內容,並確保為尋求治療的患者提供適切的照護層級。第二季期間,我們透過新增 14 個門診方案(PHP、IOP 與虛擬服務)來擴充治療選項;自年初以來,我們已在部分設施新增 23 個 PHP/IOP,以協助患者在離開住院與住宿式治療後的後續照護。透過這 5 條成長路徑,我們已具備良好條件維持強勁成長軌跡,並達成我們對 2023 年曆年的既定發展目標如下:透過既有設施新增約 300 床、合計新增約 670 床(其中今年迄今已開設 204 床);開設 2 家住院型自建(de novo)新院;與合資夥伴開設 2 家醫院(我們已於第三季初完成);以及至少新增 6 個 CTC 據點(包含前述已開設的 2 個)。
In addition to expanding our market reach to meet the increasing demand for our services, we're focused on making the right strategic investments to enhance our service offerings and drive favorable clinical outcomes. Importantly, we remain committed to quality in every aspect of our operations. We strive to set the standard for clinical excellence by utilizing our enterprise-wide quality and safety platform, which supports consistent and effective compassionate care delivery. We continue to make investments in our technology platform, leadership development, staff and treatment programming with a common goal to deliver the best possible outcome for our patients. As Acadia continues to grow, we're also committed to strengthening the technology and systems that underpin our operations. Our investment in electronic medical records, for example, is focused on improving clinical standardization, workflow, clinician experience and ultimately, the quality and efficiency of the care we deliver for our complex patients.
除了擴大我們的市場觸及以滿足對我們服務日益增加的需求之外,我們也專注於進行正確的策略性投資,以強化我們的服務內容並推動有利的臨床結果。重要的是,我們仍致力於在營運的各個面向維持品質。我們透過全企業的品質與安全平台,支持一致且有效的同理心照護交付,努力樹立臨床卓越的標竿。我們持續投資於我們的技術平台、領導力發展、員工與治療方案設計,並以為病患帶來最佳可能結果為共同目標。隨著 Acadia 持續成長,我們也致力於強化支撐營運的技術與系統。例如,我們在電子病歷方面的投資,聚焦於提升臨床標準化、工作流程、臨床人員體驗,並最終提升我們為複雜病患提供之照護的品質與效率。
Additionally, we are investing in patient monitoring technology, which helps us ensure our foundational commitment to patient safety. This technology provides real-time visibility and feedback to our clinical staff, ensuring consistent execution across our facilities. Through the patient safety initiatives that we've implemented over the last 12 months, we are pleased with our progress and have seen positive results in patient care and fewer patient incidents. We're extremely grateful for our dedicated employees who continue to advance our purpose to lead care with light and to provide safe quality care for more patients and families who come to us for treatment during their darkest times.
此外,我們正在投資病患監測技術,以協助我們確保對病患安全的基礎承諾。該技術為我們的臨床人員提供即時可視性與回饋,確保在各院區一致執行。透過我們在過去 12 個月所推行的病患安全措施,我們對進展感到滿意,並在病患照護方面看到正面成果,且病患事件更少。我們非常感謝敬業的員工,他們持續推動我們「以光引領照護」的使命,並在更多病患與家庭於最黑暗的時刻前來接受治療時,提供安全且高品質的照護。
At this point, I will now turn the call over to Heather to discuss our financial results for the quarter in our 2023 guidance.
接下來,我將把電話交給 Heather,討論本季的財務結果以及我們 2023 年的指引。
Gretchen Hommrich - VP of IR
Gretchen Hommrich - VP of IR
Thanks, Chris, and good morning, everyone. I'm honored to be with you today as Acadia's new Chief Financial Officer and look forward to working with this extraordinary leadership team. Acadia has significant opportunities to deliver high-quality care to our patients and sustainable value to our stockholders, and I'm excited to partner with Chris and the management team to further enhance our scope of services and extend our market reach.
謝謝你,Chris,各位早安。很榮幸今天能以 Acadia 新任財務長的身分與各位同在,並期待與這個卓越的領導團隊合作。Acadia 擁有重大機會,能為病患提供高品質照護,並為股東創造可持續的價值;我也很期待與 Chris 及管理團隊攜手,進一步強化我們的服務範疇並擴大市場觸及。
Now looking at the results for the quarter. Our second quarter financial performance showed continued momentum through the first half of 2023. We achieved solid top line growth with $731.3 million in revenue for the quarter, up 12.2% over the second quarter of last year. During the second quarter of 2022, the company recorded income of $8.6 million related to the Provider Relief Fund established by the CARES Act, income. Adjusted EBITDA for the second quarter of 2023 increased 10.9% to $194.5 million compared with $157.3 million for the second quarter of 2022. And adjusted income attributable to Acadia stockholders per diluted share was $0.92, up 9.5% for the second quarter of '23 compared with $0.84 for the second quarter of 2022.
現在來看本季的結果。我們第二季的財務表現延續了 2023 年上半年持續向上的動能。本季營收為 7.313 億美元,較去年第二季成長 12.2%,實現穩健的營收成長。2022 年第二季,公司認列與《CARES 法案》所設立之醫療提供者紓困基金(Provider Relief Fund)相關的 860 萬美元收入。2023 年第二季調整後 EBITDA 較 2022 年第二季的 1.573 億美元成長 10.9%,至 1.945 億美元。按稀釋後每股計,歸屬於 Acadia 股東的調整後淨利為 0.92 美元,較 2022 年第二季的 0.84 美元成長 9.5%。
Adjustments to income for the second quarter of 2023 include transaction-related expenses, loss on impairment and the related income tax effect. We remain focused on maintaining a strong financial position, providing us the flexibility and access to capital to support our organic growth strategy and future investments. As of June 30, 2023, we had $112.2 million in cash and cash equivalents and $505 million available under our $600 million revolving credit facility with a net leverage ratio of approximately 2x.
2023 年第二季的淨利調整項目包括交易相關費用、減損損失及其相關所得稅影響。我們仍專注於維持強健的財務狀況,使我們具備彈性與資本取得能力,以支持內生成長策略與未來投資。截至 2023 年 6 月 30 日,我們持有 1.122 億美元的現金及約當現金,並在 6 億美元的循環信貸額度下尚有 5.05 億美元可用,淨槓桿比率約為 2 倍。
Before I discuss our updated guidance for the full year, I want to touch on the 8-K, we filed on July 11, 2023, regarding the Desert Hills verdict and related litigation in New Mexico. Since that filing, there have been no developments and we have nothing new to report. In accordance with the accounting guidance, we have maintained our professional liability reserves related to this matter, consistent with the amounts recorded in prior periods. We are evaluating all legal options and intend to challenge the verdict. Given this is ongoing litigation, we will not be providing additional commentary regarding this legal matter on today's call.
在我討論我們更新後的全年指引之前,我想先提及我們於 2023 年 7 月 11 日提交的 8-K,內容涉及新墨西哥州 Desert Hills 的裁決及相關訴訟。自該次申報以來,沒有任何進展,我們也沒有新的資訊可報告。依據會計準則指引,我們已維持與此事項相關的專業責任準備金,並與前期所認列的金額一致。我們正在評估所有法律選項,並打算對該裁決提出挑戰。鑑於此為進行中的訴訟,我們在今天的電話會議上將不再就此法律事項提供進一步評論。
Now turning to guidance. As noted in our press release, we are increasing our financial guidance for the full year, which includes a new nominal range of $2.86 billion to $2.9 billion, adjusted EBITDA now in a range of $655 million to $685 million and adjusted and adjusted earnings per diluted share in a range of $3.25 to $3.50. Please refer to our press release for all other metrics that we affirmed. As a reminder, the company's guidance does not include the impact of any future acquisitions, divestitures, transaction-related expenses or the recognition of additional provider release fund income.
接著談指引。如同我們在新聞稿中所述,我們上調了全年財務指引,包括營收新的名目區間為 28.6 億至 29.0 億美元,調整後 EBITDA 目前區間為 6.55 億至 6.85 億美元,以及按稀釋後每股計之調整後(以及調整後)每股盈餘區間為 3.25 至 3.50 美元。其他我們所確認的指標,請參閱新聞稿。提醒各位,公司指引不包含任何未來併購、資產處分、交易相關費用,或認列額外醫療提供者紓困基金收入的影響。
With that, operator, we're ready to open the call for questions.
以上,接線員,我們準備開放提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
Our first question comes from Andrew Mok with UBS.
我們的第一個問題來自 UBS 的 Andrew Mok。
Andrew Mok - Analyst
Andrew Mok - Analyst
Maybe first question just on guidance. You beat Street estimates by about $7 million and raised the guide by $15 million. Just wanted to better understand the strengthening trends that you're seeing and that prompted you to raise the outlook for the back half of the year? And any color on the second half pricing outlook would be helpful?
第一個問題可能是關於指引。你們的表現比市場預估高出約 700 萬美元,並將指引上調 1,500 萬美元。想更了解你們看到哪些走強的趨勢,促使你們上調下半年展望?另外,也希望能提供一些下半年定價展望的補充說明。
Heather Dixon - CFO
Heather Dixon - CFO
Sure. Thanks for the question, Andrew. So first of all, I just want to reiterate that we're very pleased to see the strong results and the operating trends that we had for the first half of 2023. And I would point to a few things that are really driving the confidence that we have to look towards the back half of the year. The first is volume trends, reflecting strong demand, occupancy rates and capacity additions. The second is improved visibility into the back half of the year for our revenue per day. We expect that to continue for the full year to be in mid-single digits. And then finally, I would point to labor costs continuing to moderate throughout the year.
好的。謝謝你的問題,Andrew。首先,我想重申,我們很高興看到 2023 年上半年強勁的結果與營運趨勢。我會指出幾個因素,正是這些因素驅動我們對下半年展望的信心。第一是量的趨勢,反映出強勁需求、入住率以及產能增加。第二是我們對下半年「每日營收」的能見度提升;我們預期全年將持續維持在中個位數成長。最後,我會指出人力成本在全年持續趨於緩和。
Andrew Mok - Analyst
Andrew Mok - Analyst
Got it. Maybe just a follow-up on the labor. Sequentially, SWB stepped down in the quarter, which booked historical trends and possibly steps over some April merit increases. Can you flesh out the drivers of the sequential decline? And if we look at SWB per patient today, is the expectation from here that you'll hold that flat such that the year-over-year increase steps down meaningfully in the back half of the year?
了解。再追問一下人力方面。SWB 在本季按季下降,這符合歷史趨勢,也可能跨過了 4 月的調薪(merit increases)。你能否更具體說明按季下降的驅動因素?另外,如果我們看目前每位病患的 SWB,接下來的預期是否是維持持平,使得下半年年增率明顯下滑?
Heather Dixon - CFO
Heather Dixon - CFO
Sure. Sure. Let me take those one at a time. So I would say, partially, you're right. What we did see is some seasonality that's coming through from Q1 to Q2. If you remember, in the first quarter, we have about 70% of our employee base merit increases that come through, and in the second quarter, in April, we have the remaining 30% of those that come through. I mean, those are addressed according to the geographic markets, the performance job categories, et cetera. But generally speaking, it's about a 70-30 split. In addition, we have seasonality in the payroll taxes that we see that come through in the first quarter of every year.
當然。當然。我逐一回答。我會說,部分而言,你的判斷是對的。我們確實看到從第一季到第二季的季節性因素。如果你記得,第一季大約有 70% 的員工調薪會生效,而第二季的 4 月則是剩餘 30% 生效。這些調整會依地理市場、績效、職務類別等而定,但整體而言大約是 70/30 的分布。此外,我們也會在每年第一季看到薪資稅的季節性影響。
So for sure, there's a portion of that, that you're seeing in that sequential decline. And that said, I would say that we expect to see that hold flat and to continue to moderate overall. We are seeing improvements in the labor trends and we would expect to see that to continue. The base wage inflation went down about 120 basis points from 7.5% in Q1 to 6.3% in Q2, and we would expect to see that to continue to moderate throughout the back half of the year.
所以可以確定的是,你在那個按季下降中看到的,有一部分就是上述因素所致。話雖如此,我會說我們預期這將維持持平,並在整體上持續趨於緩和。我們看到人力趨勢正在改善,並預期這種改善會持續。基本工資通膨從第一季的 7.5% 下降約 120 個基點至第二季的 6.3%,我們預期在下半年將持續緩和。
Operator
Operator
Our next question comes from Whit Mayo with in Leerink Partners.
我們的下一個問題來自 Leerink Partners 的 Whit Mayo。
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
Welcome, Heather. Chris, maybe just to start, just a strategic question. I mean I think you've been sort of identifying some field-level initiatives around cost management, specifically, maybe standardization opportunities in the back-office, IT, administrative functions. Just where maybe you see some of the largest organic growth opportunities on the cost side to standardize some of those functions and maybe any way to put some numbers around it?
歡迎你,Heather。Chris,或許先從策略面開始問。我想你們一直在辨識一些現場層級、與成本管理相關的措施,特別是後勤、IT、行政職能等方面的標準化機會。你們在哪些成本端的領域看到最大的內生成長機會,可以透過標準化這些職能來實現?以及是否有任何方式可以用數字量化?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. I think -- thanks for the question, Whit. And there were a number of things that we have had ongoing. I mean, clearly, we see technology as an opportunity for us to not only achieve efficiencies in the business, but we're also seeing some real improvements on the safety side and clearly just evidence of being able to produce greater clinical outcomes. I know that everyone would like to see more detail on some of the efficiencies that these IT investments will drive, and I think we'll have that in short order. I would say in the near term, the results that we're seeing from the EMR installations that we've seen to date have been extremely beneficial in that we have seen not only really solid feedback from surveyors and regulators that have been into our facilities, but we're also seeing a really nice uptick in employee engagement for those facilities where we do have an EMR in place, which has really helped us on the recruitment front, and we think will continue to help us on the retention front as we roll those out as well.
是的。我想——謝謝你的提問,Whit。我們確實有幾項工作一直在持續推進。我的意思是,很明顯地,我們把科技視為一個機會,不僅能在業務上提升效率,同時我們也在安全面看到一些實質改善,並且清楚看到能夠帶來更佳臨床結果的證據。我知道大家都希望看到更多關於這些 IT 投資將帶來哪些效率提升的細節,我想我們很快就會提供。我會說,短期內,我們迄今所完成的 EMR(電子病歷)導入成果非常有利:我們不僅從進入我們機構的稽核人員與監管單位那裡獲得非常正面的回饋,同時在已導入 EMR 的機構,我們也看到員工敬業度明顯提升,這確實在招募方面幫了大忙,而且我們認為隨著持續推廣,也會在留任方面繼續帶來助益。
And then we alluded in the prepared remarks to some of the remote monitoring software that we've been able to put in place that also has proven some really strong benefits to our patients as well. And I think overall, just given how paper-intensive this industry has been, we just know that we're going to continue to see back office improvement as time goes on as well. So those are just some of the broader things. I mean, clearly, as we continue to roll out the EMR across all of our acute facilities, we'll continue to see greater efficiencies. But I think the point I would want to make is that we are already seeing the benefit to date on the patient engagement side and on the employee engagement side and also just with these surveyors and regulators already.
另外,我們在事先準備的發言中也提到,我們已部署的一些遠端監測軟體,也已證明能為病患帶來非常顯著的效益。整體而言,鑑於這個產業過去高度依賴紙本作業,我們知道隨著時間推進,後台作業也會持續改善。所以以上是一些較宏觀的面向。我的意思是,隨著我們持續在所有急性照護機構推動 EMR 上線,我們將會看到更高的效率。但我想強調的是,截至目前,我們已經在病患參與度、員工參與度,以及面對稽核人員與監管單位等方面,看到實際的效益。
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
Benjamin Whitman Mayo - MD of Equity Research & Senior Research Analyst
And last question, just views on the physician fee schedule, the proposal there, the impact on the CTC business? And maybe any updated thoughts on the opioid settlement, some of the states are disclosing now direct support to OTP program, so wondering if you had any updated views?
最後一個問題,想請教你們對醫師費用表(physician fee schedule)以及相關提案的看法,對 CTC 業務的影響?另外,關於阿片類藥物和解(opioid settlement)是否有任何更新的想法?有些州現在開始揭露對 OTP 計畫的直接支持,所以想知道你們是否有更新的觀點?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. I mean clearly, we continue to watch the CTC, the settlement dollars very closely. $54 billion, again, have been allocated, only about $3 billion of the total settlement funds have been dispersed to this date. There was a report that we saw earlier this summer by Reuters that only 16 states right now actually have a central statewide publicly available process for organizations to apply for funding. But we have been successful in applying for and receiving funds early on. Usually, this is at the individual county level.
是的。我的意思是,很明顯地,我們持續非常密切地關注 CTC 以及和解資金的動向。540 億美元再次強調已完成分配,但截至目前,整體和解資金中只有約 30 億美元已實際撥付。我們在今年夏初看到路透社(Reuters)的一份報告指出,目前只有 16 個州真正建立了全州層級、集中且對外公開的申請流程,讓機構可以申請資金。不過,我們在早期就成功申請並取得資金;通常這些是在各個郡(county)層級進行。
And to date, it's been for things like harm-reduction services and wraparound care, things like case management and even housing support. But I would just say it's still very early days. We've bolstered some of our capabilities there and continue watching and tracking these grants as they come over and think that we'll continue to be really well positioned for that. But overall, I think we just continue to be really optimistic here.
截至目前,資金主要用於例如減害(harm-reduction)服務與整合式支持照護(wraparound care),像是個案管理,甚至住房支持。但我想說,現在仍然是非常早期的階段。我們已強化了相關能力,並持續關注與追蹤這些補助案的釋出,我們認為自己會持續處於非常有利的位置。整體而言,我想我們仍然保持非常樂觀。
70% of the money that has actually is received by states has to be spent on future opioid remediation efforts. And so we feel great about that and the transparency that we're beginning to see. I think there's 15 states now that have explicitly promised to publicly report 100% of their settlement expenditures, which is really a contrast to the way the tobacco settlements worked out. So it's still very early stages here. We've bolstered our team on the CTC side and just continue to feel very positive about our ability to continue to win many of these awards as they continue to come out. But clearly, this will accelerate into '24 and well into '25 as well.
各州實際收到的資金中,有 70% 必須用於未來的阿片類藥物補救(remediation)工作。因此我們對此感到非常振奮,也對目前開始出現的透明度感到很正面。我想現在有 15 個州已明確承諾將公開報告其 100% 的和解支出,這與菸草和解案當年的運作方式形成強烈對比。所以目前仍在非常早期階段。我們已在 CTC 端擴編團隊,並持續對我們能夠在後續陸續釋出的補助案中贏得許多獎助(awards)的能力感到非常正向。但很明顯地,這將在 2024 年加速,並延續到 2025 年。
Operator
Operator
Our next question comes from A.J. Rice with Credit Suisse.
我們的下一個問題來自 Credit Suisse 的 A.J. Rice。
Albert J. William Rice - Research Analyst
Albert J. William Rice - Research Analyst
Just maybe first to delve in a little bit more on the pricing for the back half of the year and year ahead. You had, I think, back in February when you gave the fourth quarter release, there have been some discussion, and it actually created a little bit of confusion that the company was at least baking into guidance at that point, the possibility of a moderation in pricing in the back half of the year as pricing has been pretty robust. It sounds like you're feeling a little better about the sustainability at least the level you're at now. Can you just comment on whether I'm hearing that right? And does that tend to concentrate more on what you're seeing on the Medicaid side, on the commercial side, any thoughts on that?
我想先更深入問一下今年下半年以及明年的定價情況。我記得你們在 2 月發布第四季財報時,曾有一些討論,甚至造成一點混淆:公司當時在指引中似乎至少納入了下半年定價可能趨緩的可能性,因為定價一直相當強勁。聽起來你們對目前水準的可持續性更有信心。你能否評論一下我是否理解正確?另外,這是否更集中反映在 Medicaid 端、商業保險端,或你們看到的其他面向?對此有何想法?
Heather Dixon - CFO
Heather Dixon - CFO
Yes, you are hearing that correctly. You are correct that we had anticipated some moderation in the revenue per day and the rates in the back half of the year previously. But as we've finalized the number of the Medicaid and commercial rate increases since the last time we spoke to you, many of which have effective dates as of July 1. We're seeing much more direct visibility into the second half of the year. I mean the experience can, of course, vary by market and payer, but we continue to see average rate increases in the mid-single digits. And so that's now what we're projecting for the back half of the year is for that continued mid-single-digit growth across all service lines, including CT we'll expect to see that continued growth.
是的,你聽得沒錯。你說得對,我們先前確實預期今年下半年每床日收入(revenue per day)與費率會有一些趨緩。但自從上次與你們交流以來,我們已敲定 Medicaid 與商業保險的多項費率調升,其中許多自 7 月 1 日起生效。因此,我們對下半年有更直接的能見度。當然,實際情況會因市場與付款方而異,但我們仍持續看到平均費率調升落在中個位數(mid-single digits)。因此,我們目前對下半年的預測是:所有服務線都將延續中個位數的成長,包括 CT,我們也預期會持續成長。
Albert J. William Rice - Research Analyst
Albert J. William Rice - Research Analyst
Okay. And then just maybe on the follow-up, the Turning Point deal looks like an interesting one. Maybe just spend a minute talking about that opportunity? And I know one thing with the development pipeline in general in the M&A pipeline. There was a time when we had to think about start-up losses associated with that, those pipelines. It doesn't seem like that's as much of a headwind for you. And I wondered if I'm hearing that right? And why might that be the case? You seem like you're managing that a little better in terms of the potential costs and so forth of all the new development you're pursuing?
好的。接著追問一下,Turning Point 這筆交易看起來很有意思。能否花點時間談談這個機會?另外,就整體開發管線與併購(M&A)管線而言,過去我們需要考量與這些管線相關的開辦期虧損(start-up losses)。但看起來這對你們似乎不再是那麼大的逆風。我想確認我是否理解正確?以及為什麼會是這樣?你們似乎在管理新開發所帶來的潛在成本等方面做得更好?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes, A.J., this is Chris. Thanks for the question. Why don't I take turning point, and I'll let Heather just speak to the start-up loss question that you have. But first on Turning Point, we feel great about the ability to announce this transaction. I mean, this is the first time that we have been able to have all 4 lines of business in 1 geographic region in Salt Lake City. This is a nice opportunity for us, 76-bed specialty provider of substance use disorder and primary mental health treatment services. We expect it to close by the end of the year and are already beginning to work on the integration related to that. This is one where just our ability to extend our specialty footprint, but also the synergies with our other lines of business, just had made this one particularly attractive. This is a proprietary transaction that we identified and sourced ourselves.
是的,A.J.,我是 Chris。謝謝你的提問。Turning Point 的部分我先回答,至於你提到的開辦期虧損問題,我讓 Heather 來說明。先談 Turning Point,我們對能夠宣布這筆交易感到非常振奮。我的意思是,這是我們第一次能在鹽湖城同一個地理區域內,擁有 4 條業務線。這對我們是一個很好的機會:它是一家擁有 76 張床位的專科服務提供者,提供物質使用障礙(substance use disorder)以及主要心理健康治療服務。我們預期在年底前完成交割,並且已開始進行相關整合工作。這筆交易之所以特別具吸引力,是因為它不僅能擴大我們的專科版圖,也能與我們其他業務線產生協同效益。這是一筆我們自行辨識並取得來源的專屬交易(proprietary transaction)。
And when we have historically looked back at those acquisitions that have been most successful at Acadia, the ability to have expansion opportunity has proven really important. And this is one where we think we can add an incremental 48 beds to the 76 beds that they currently have over time. So that really was a deciding factor for us on this transaction. And we do expect, while this won't close until the end of the year, that the acquisition will be accretive in its first year. So Heather, do you want to speak to the start-up loss question?
而且,當我們回顧 Acadia 歷史上最成功的那些收購案時,具備擴張機會的能力一直被證明非常重要。這一案我們認為,隨著時間推進,我們可以在其現有 76 張床位的基礎上,額外增加 48 張床位。因此,這確實是我們決定進行這筆交易的一個關鍵因素。我們也預期,雖然這筆交易要到年底才會完成,但在收購完成後的第一年就會具增益性(accretive)。Heather,你要不要談談開辦期虧損的問題?
Heather Dixon - CFO
Heather Dixon - CFO
Sure. In terms of the start-up losses, we do continue to project those to be fairly consistent. We usually expect them to be between $15 million and $20 million a year, and that's consistent with what we saw in Q2 of $5.4 million, and we would expect for that to continue to be roughly that same amount per quarter. As we think about how we moderate the scheduling of the openings and how you think about new facilities opening roll in and then facilities that ramp roll out of that calculation, we just expect that to stay pretty stable.
好的。就開辦期虧損而言,我們仍預期會維持相當一致的水準。通常我們預期每年約在 1,500 萬至 2,000 萬美元之間,這也與第二季的 540 萬美元一致;我們預期未來每季大致也會維持在相近的金額。當我們思考如何調整開業時程安排,以及新設施開業逐步納入、而已爬坡完成的設施逐步退出該計算時,我們預期這個數字會保持相當穩定。
Operator
Operator
Our next question comes from John Ransom with Raymond James.
我們的下一個問題來自 Raymond James 的 John Ransom。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
A 2-parter for me. Number one, if you look at your pre-overhead margins, they're about as high as they've been. What do you think the ceiling is for those margins, number one? And then number two, you have an idea like what the spending per hospital is going to look like when you roll out -- fully roll out your EMR?
我這邊有兩個問題。第一,如果你看你們扣除總部間接費用前(pre-overhead)的利潤率,幾乎已經是你們歷來最高水準。你認為這些利潤率的上限在哪裡?第二,當你們把 EMR 完整推廣(fully roll out)之後,你們對每家醫院的支出大概會是什麼樣子,有沒有概念?
Heather Dixon - CFO
Heather Dixon - CFO
So maybe I'll speak to what I think you're asking is the corporate overhead sort of cost. And if we see that stabilizing over the period to period, we would...
所以也許我先回應我理解你在問的,是公司總部間接費用(corporate overhead)這類成本。若我們看到它在各期之間趨於穩定,我們會……
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
No, no, no. I'm actually asking the pre-overhead hospital margins in the high 20s, what do you think the feeling is not -- it's pre-overhead. What do you think the feeling is for the pre-overhead hospital margins as you sit today?
不不不。我其實是在問扣除總部間接費用前的醫院利潤率,目前在 20% 高段(high 20s)。你認為這個水準的上限是什麼——這是 pre-overhead。以你們目前的狀況來看,你覺得 pre-overhead 的醫院利潤率大概會落在哪裡?
Heather Dixon - CFO
Heather Dixon - CFO
Okay. Thanks. I understand. So I would say that we continue -- we expect we can see that to be a continued strong margin as we look at what those will contribute.
好的,謝謝。我明白了。所以我會說,我們會持續——我們預期這仍會是強勁的利潤率,因為我們在看這些業務將帶來的貢獻。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
And then the EMR spending for hospitals?
那醫院端的 EMR 支出呢?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes, John, sorry, can you -- you cut out on the tail end of that. What specifically was the question around EMR?
是的,John,不好意思,你最後那一段聲音斷掉了。關於 EMR,你具體想問的是哪一點?
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
Sorry. So the EMR, you provided a range at your Analyst Day. But as you think about your EMR spending, have you landed on a kind of rollout schedule and a cost per hospital on that line item?
抱歉。關於 EMR,你們在分析師日(Analyst Day)提供了一個區間。但就你們的 EMR 支出來看,你們是否已經確定一個推廣時程(rollout schedule),以及在那個費用項目下每家醫院的成本?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. We're still working through that. I mean, I would say that what we've laid out in our Investor Day continues to be very consistent. We broke that out between CapEx and OpEx. And I would say we're still very much tracking there. I think one of the things we're looking at, just given the early results that have been very attractive as we've continued to bring a number of these acute facilities up on an EMR is can we even go a little bit faster. Right now, we've had a plan to roll all of our acute facilities out over a 2-year period. And we're looking closely with others help at whether or not it would make sense for us to accelerate that, but we're still -- we haven't disclosed the cost per facility I think most importantly, what we laid out at Investor Day continues to be very much on track.
是的,我們仍在推進相關工作。我會說,我們在投資人日(Investor Day)所說明的內容仍然非常一致。我們把它拆分為資本支出(CapEx)與營運支出(OpEx),而且我會說我們目前仍然非常符合那個軌道。我想我們正在評估的一件事是:鑑於早期成果非常吸引人,隨著我們持續讓多家急性照護機構(acute facilities)上線 EMR,我們是否能再快一些。目前我們的計畫是在 2 年內把所有急性照護機構完成上線。我們正與其他人協助下密切評估是否有必要加速,但我們仍——我們尚未披露每個機構的成本。我認為最重要的是,我們在投資人日所提出的規劃仍然非常按計畫進行。
Operator
Operator
Our next question comes from Kevin Fishbeck with Bank of America.
下一個問題來自美國銀行(Bank of America)的 Kevin Fishbeck。
Unidentified Analyst
Unidentified Analyst
This is Nabil on for Kevin. Can you talk about how volumes trended across the different segments in the quarter? And how are you thinking about growth in the second half of the year?
我是代 Kevin 提問的 Nabil。你能談談本季不同業務分部的量(volumes)趨勢嗎?以及你們如何看待下半年成長?
Heather Dixon - CFO
Heather Dixon - CFO
Sure. So we have seen strong demand in patient volumes during the second quarter, as we've been saying. The last 3 years of same facility volume growth has been roughly in the 2% to 4% range, and we've been really highly focused on delivering volume growth acceleration. And the opportunities that we've identified have led us to really point to 4% to 6% percent growth expectation for 2023. We really attribute that and some record patient census levels to a few things. First is demand across the service lines. Second is optimization and our marketing and admissions processes. Third, the stronger occupancy rates that are driven by that demand and the operational execution. And then finally, I'd just point to the recent bed additions that we mentioned. We had 212 that we added in the second half of '22, and then we combine that with another 204 in the first half of 2023. And that's really what's driving us to be well positioned, I think, to hit that 4% to 6% range for the second half of the year.
當然。我們在第二季看到病患量(patient volumes)需求強勁,正如我們一直在說的。過去 3 年同院(same facility)量的成長大約在 2% 到 4% 區間,而我們一直高度聚焦在推動量的成長加速。我們所辨識的機會,使我們對 2023 年提出 4% 到 6% 的成長預期。我們把這點,以及一些創新高的住院人數(patient census)水準,歸因於幾個因素:第一,各服務線(service lines)的需求;第二,我們在行銷與收案(admissions)流程上的優化;第三,由需求與營運執行帶動的更高入住率(occupancy rates);最後,我也要提到我們近期新增的床位。我們在 2022 年下半年新增了 212 床,並在 2023 年上半年再新增 204 床。這些因素讓我們在我看來具備良好條件,在下半年達成 4% 到 6% 的區間。
Unidentified Analyst
Unidentified Analyst
And then for the follow-up, can you provide us an update on redeterminations and what your guidance is assuming on the impact?
追問一下,你能否更新一下重新資格審查(redeterminations)的進度,以及你們的指引(guidance)假設其影響為何?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Sure. This is Chris. We've been working on redetermination since late last year and continued to just be a really major focus for the company across all of our service lines. And as of July 1, every 1 of our states except for Oregon is now launched. So that said, I would say, only a fraction of our patients under 25% have completed redetermination due to the way that so many of these states continue to spread the disenrollment through all the way into 2024. So as we've previously discussed, we're seeing good early results in our patients maintaining coverage. I would say on our RTC service line, those children are increasingly protected because 80% of Medicaid patients are awards of the state.
當然。我是 Chris。我們自去年底以來就一直在處理重新資格審查(redetermination),並且持續把它作為公司在所有服務線上的重大重點。截至 7 月 1 日,除了俄勒岡州(Oregon)之外,我們所有州別都已啟動。即便如此,由於許多州仍把退保(disenrollment)分散安排一路延伸到 2024 年,因此目前完成重新資格審查的病患僅占一小部分,不到 25%。如我們先前討論的,我們在病患維持保險覆蓋(coverage)方面看到不錯的早期結果。我會說在我們的 RTC 服務線上,這些兒童受到的保護程度更高,因為 80% 的 Medicaid 病患是州政府的監護對象(wards of the state)。
On our specialty service line, those Medicaid recipients are also protected due to the unique county-level backstop funding that we have in place for patients in Pennsylvania where we have most specialty Medicaid volume. And then on the CTC side, I mean we just continue working very closely with our patients to ensure that they have visibility as to whether there could be some disruption. We're seeing some patients moving to self-pay in a few cases. But overall, we're really encouraged by our ability to work with these patients to use the hot line we put in place, the kiosks that we put in so many of our centers.
在我們的專科(specialty)服務線上,這些 Medicaid 受益人也受到保護,因為我們在賓夕法尼亞州(Pennsylvania)針對病患設有獨特的郡級(county-level)後盾資金(backstop funding),而我們的大部分專科 Medicaid 量也在那裡。至於 CTC 端,我們則持續與病患非常密切合作,確保他們能清楚了解是否可能出現中斷。我們確實看到少數情況下有些病患轉為自費(self-pay)。但整體而言,我們對於能與這些病患合作、使用我們設立的專線(hot line)以及在許多中心設置的自助機台(kiosks)感到非常鼓舞。
And I think it's done -- it's been very successful in ensuring continuity of care overall. Maybe a couple of other things I'd just point out. I mean, clearly, everyone has read about CMS's action to pause redetermination in a handful of states. And I would point to some of the Kaiser Family Foundation data that came out early this month, that said the 3 million people that have been disenrolled for Medicaid since redetermination began in April.
我認為這在確保整體照護連續性(continuity of care)方面——一直非常成功。我再補充幾點。很明顯,大家都讀到 CMS 在少數州暫停重新資格審查的行動。我也想引用本月初凱撒家庭基金會(Kaiser Family Foundation)的資料,指出自 4 月重新資格審查開始以來,已有 300 萬人被取消 Medicaid 資格(disenrolled)。
Of those disenrolled, 74% were due to procedural reasons rather being disenrolled due to ineligibility for Medicaid. So clearly, CMS is encouraging a number of states to just slow the process down. We continue to see some pretty wide variation in terms of the way that states are handling redetermination. So you have some states that are scheduling members really early in the unwind period like Florida. Others are taking the opposite approach where they're really back-end loading the disenrollment a member of Michigan and Oklahoma would be examples there.
在這些被取消資格的人當中,74% 是因程序性原因(procedural reasons)而被取消,而不是因為不符合 Medicaid 資格(ineligibility)而被取消。因此很明顯,CMS 正鼓勵一些州放慢流程。我們仍看到各州在處理重新資格審查方式上存在相當大的差異。有些州在解封(unwind)期間很早就安排成員,例如佛羅里達州(Florida)。另一些州則採取相反作法,把退保更多集中在後段,例如密西根州(Michigan)與奧克拉荷馬州(Oklahoma)就是例子。
You also have some states that are just doing a great job of giving us transparency into when patients are going to lose coverage. Virginia and Tennessee would be examples there. That gives us an opportunity to be proactive and to reach out to these patients in advance of potentially being removed from the Medicaid roles, and we've seen that working really well. So all in all, I'd say it's still early. The process does very significantly stay to today. We're continuing to track it very closely on a number of levels, but we continue to believe the overall impact is going to be more, particularly in '23, and our early experience just continues to align pretty well with that view.
你也會看到有些州在提供病患何時會失去保險覆蓋方面做得非常好,維吉尼亞州(Virginia)與田納西州(Tennessee)就是例子。這讓我們有機會更主動,在病患可能被移出 Medicaid 名冊(roles)之前提前聯繫他們,而我們看到這運作得非常好。總體而言,我會說現在仍屬早期。到目前為止,流程仍有很大程度的差異。我們在多個層面持續非常密切地追蹤,但我們仍相信整體影響會較為溫和(more),尤其是在 2023 年,而我們的早期經驗也持續與這個看法相當一致。
Operator
Operator
Yes. next question comes from Gary Taylor with Cowen.
好的。下一個問題來自 Cowen 的 Gary Taylor。
Gary Paul Taylor - MD & Senior Equity Research Analyst
Gary Paul Taylor - MD & Senior Equity Research Analyst
Just a couple of questions. One, I just want to clarify. When you talk about wage inflation, how are you defining that? Is that just average hourly rate, excluding benefits, I don't know if over time or contract labor would be in there. But since we can't quite reconcile that, we can only look at the reported figure? I just want to make sure I understand how you define that. When you talk about 7.5 going to the 6.3?
我有兩個問題。第一,我想釐清一下:當你們談到薪資通膨(wage inflation)時,你們是如何定義的?那只是平均時薪(average hourly rate)嗎?是否不含福利(excluding benefits)?我不確定長期來看或合約勞務(contract labor)是否包含在內。但因為我們無法完全對得上,只能看你們揭露的數字,所以我想確認我理解你們的定義。當你們說 7.5 降到 6.3 的時候,你們指的是什麼?
Gretchen Hommrich - VP of IR
Gretchen Hommrich - VP of IR
You are thinking about that correctly. They are excluded, but I would add that they're stable across the board.
你的理解是正確的。那些是被排除的(excluded),但我會補充,它們在各方面都保持穩定。
Gary Paul Taylor - MD & Senior Equity Research Analyst
Gary Paul Taylor - MD & Senior Equity Research Analyst
Okay. And then my second 1 would just be on the new medical settlements. I know you're hopeful that will be reversed on appeal. My question, though, since it is fairly material out. Is there -- does it have any impact -- it sounds like no on the investment you're willing to make on de novo Bronson facilities in the near term. But any other impact just in terms of how you're thinking about balance sheet management or even just retaining credit availability, anything material to say on how you're thinking about that at this point?
好的。第二個問題是關於新的醫療和解(new medical settlements)。我知道你們希望上訴後能被推翻。不過我的問題是,既然金額相當重大:它是否會帶來任何影響——聽起來對你們短期內願意在新設(de novo)的 Bronson 設施上投入的投資沒有影響。但除此之外,對於你們如何思考資產負債表管理(balance sheet management),甚至是維持信貸可用性(credit availability),目前有沒有任何重大影響或可分享的看法?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. Thanks for the question. This is Chris. I would just say that we obviously are tracking this very closely. And as I think you can tell from the execution that we've seen just in the last few weeks and announcing 2 JVs and an M&A deal, we continue to be extremely focused on the core business and continuing to advance the company and all the things that we laid out on our Investor Day. So we do not see any material change at all. And obviously, we're not going to be talking in detail about the litigation and given that, that is underway, but we are super focused on the business as I think our results reflect.
是的。謝謝你的提問。我是 Chris。我想說的是,我們顯然正非常密切地追蹤這件事。而且正如你從我們在過去幾週所看到的執行成果——宣布了 2 項合資(JV)以及一筆併購(M&A)交易——我們仍然極度專注於核心業務,並持續推動公司前進,以及我們在投資人日所闡述的所有事項。因此,我們沒有看到任何重大變化。當然,鑑於訴訟正在進行中,我們不會就訴訟細節進行討論;但我們對業務的專注程度非常高,我想我們的業績也反映了這一點。
Operator
Operator
The next question comes from Pito Chickering with Deutsche Bank.
下一個問題來自德意志銀行(Deutsche Bank)的 Pito Chickering。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Congrats on an excellent quarter and Heather welcome to the team. A follow-up to A.J.'s question. With pricing gets continuing single digits in the back half of the year, that would make sort of over 2 years with pricing tracking at mid or above mid-single-digit range. As you sort of look at your contracting you have today in the sort of confidence back half year, is that the right level that we should be thinking about for 2024?
恭喜你們交出非常出色的一季,也歡迎 Heather 加入團隊。我想追問 A.J. 的問題。若定價在今年下半年仍維持個位數成長,那等於定價已連續超過兩年維持在中個位數或高於中個位數的區間。當你們看目前的合約狀況,以及對下半年的信心時,這是否是我們在思考 2024 年時應該預期的合理水準?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes, Peter, this is Chris. Thanks for the question. I would say that we continue to work really closely with our managed care team and with our payer partners. And I think that the reimbursement levels that we've seen, that we've discussed in the beginning of the year have continued to hold true in the second half of the year. I don't think we're ready to comment on 2024 yet. But I think we are doing a really good job of helping payers understand the acuity of our patients, the quality of care that we're providing, the inflationary impact on wages, and we're coming very prepared to those meetings and leveraging the strong partnerships that we built over a multiyear period with our payers to continue to achieve really strong rates.
是的,Peter,我是 Chris。謝謝你的提問。我會說,我們持續與我們的管理式照護團隊以及付款方合作夥伴非常緊密地合作。我認為我們所看到的、也在年初討論過的報銷水準,在今年下半年仍然維持不變。我們還沒準備好對 2024 年發表評論。但我認為我們在幫助付款方理解病患的病情嚴重度、我們提供的照護品質、薪資通膨的影響方面做得非常好;我們也以充分準備參與這些會議,並運用我們與付款方在多年期間建立的強大合作關係,持續取得非常有力的費率。
Philip Chickering - Research Analyst
Philip Chickering - Research Analyst
Okay. Great. And then one question on CDC. As like you look at the today's reimbursement model from methadone clinics, do you see a shifting in the near term away from a bundled model where you're paying a monthly fee to provide those drugs and services into more of an unbundled model or managed care splits of payments between providing the medication as the drugs and another payment for providing counting services?
好的。很好。接著一個關於 CDC 的問題。當你們看目前美沙酮診所的報銷模式時,是否看到短期內有從「打包式」(bundled)模式——也就是按月支付費用以提供藥物與服務——轉向更「拆分式」(unbundled)模式的趨勢?或是管理式照護將付款拆分為兩部分:一部分支付藥物(藥品),另一部分支付諮商服務?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. It's -- thanks for the question, Pito. And I would say we're not seeing that trend at all as of right now. We're obviously in very close contact with payers all the time and there isn't any movement towards unbundling that we have seen in our extensive negotiations that we're doing on a regular basis.
是的——謝謝你的提問,Pito。我會說,就目前而言我們完全沒有看到那樣的趨勢。我們當然一直與付款方保持非常密切的聯繫,而在我們定期進行的大量談判中,我們沒有看到任何朝向拆分計價(unbundling)的動向。
Operator
Operator
The next question is a follow-up from John Ransom with Raymond James.
下一個問題是 Raymond James 的 John Ransom 的追問。
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
John Wilson Ransom - MD of Equity Research & Director of Healthcare Research
I just wanted to circle back on the MAT. There were some concern in the marketplace about some new therapeutic options with (inaudible). And I just wondered kind of what your take is on that, if you've seen any sort of deterioration in the opportunity from that modality?
我想再回到 MAT 的話題。市場上對一些新的治療選項(聽不清)有些擔憂。我想請教你們對此的看法,以及你們是否看到這種治療方式導致機會有所惡化?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes. Well, I would say -- thanks, John. Methadone continues to be the gold standard for treatment. And we continue to provide buprenorphine as well. But as we've looked at our outcomes, we just feel continuously comfortable with our approach overall. I mean I would say that our quality as well, I think, is going to continue to be very important. CARF, which is the regulatory body that provides oversight for opioid treatment programs and they're doing 3,500 site surveys annually. They came in and assessed Acadia at a 98-plus percent compliance across the board, outperforming all of the other OTPs.
是的。嗯,我會說——謝謝你,John。美沙酮仍然是治療的黃金標準。我們也持續提供丁丙諾啡(buprenorphine)。但從我們的治療結果來看,我們對整體方法一直都很有信心。我也會說,我們的品質同樣非常重要。CARF 是對鴉片類藥物治療計畫(OTP)提供監督的監管機構,他們每年進行 3,500 次場址稽核。他們來評估 Acadia,整體合規率達到 98% 以上,表現優於所有其他 OTP。
So we just continue to feel really good about our model. As we frequently say and Nosercon, the leader of our business as the physician says, this is a program, it's not a pill where there's counseling that is required. It's not just dispensing treatment. It's engaging these chronic members of these chronic patients in treatment, particularly in the early stages where their addiction is more pronounced and continuing to engage them in that treatment as they -- as their treatment evolves over a period of time. So we have not seen any trend.
因此,我們對我們的模式持續感到非常滿意。正如我們常說的,而我們業務負責人、身為醫師的 Nosercon 也表示,這是一個「計畫」,不是一顆藥;其中需要諮商。這不只是發放治療藥物,而是讓這些慢性病患持續參與治療,特別是在成癮更明顯的早期階段,並在其治療隨時間演進的過程中持續讓他們投入治療。因此,我們沒有看到任何趨勢變化。
I think you may be referring to the public health emergency, which clearly allowed doctors to provide buprenorphine for up to 30 patients in care and the data that we saw during the public health emergency was the number of scripts written per month remained largely flat relative to pre-public health emergency. And we're just not seeing any changing trends. We're continuing to see really strong volumes and just continue to feel very good about the outlook of that business and the leadership team that we've put in place.
我想你可能指的是公共衛生緊急狀態(public health emergency),它確實允許醫師為最多 30 名照護中的病患提供丁丙諾啡;而我們在公共衛生緊急狀態期間看到的數據是,每月開立的處方數相較於緊急狀態前大致持平。我們並未看到任何趨勢改變。我們持續看到非常強勁的量能,並且對該業務的前景以及我們所建立的領導團隊仍然非常有信心。
Operator
Operator
Our next question comes from Brian Tanquilut with Jefferies.
下一個問題來自 Jefferies 的 Brian Tanquilut。
Brian Gil Tanquilut - Senior Equity/Stock Analyst
Brian Gil Tanquilut - Senior Equity/Stock Analyst
Congrats, and welcome to Heather. I guess, Heather, my first question, as I think about Q3, historically, pre-COVID, there was seasonality in the business, largely driven by the RTC business, but it has gotten smaller. How should we be thinking about the Q3 sequential trend versus Q2?
恭喜,也歡迎 Heather。我想,Heather,我的第一個問題是:當我思考第三季(Q3)時,歷史上在 COVID 之前,業務存在季節性,主要由 RTC 業務驅動,但它的占比已變小。我們應該如何看待 Q3 相對於 Q2 的環比趨勢?
Heather Dixon - CFO
Heather Dixon - CFO
Thanks, and welcome and for the question. I would think about it consistently with the sequential trends that we've seen. And I would see that we're expecting sort of a sequential trends for that to continue. So I think just in line with the expectations and what you've seen previously from a seasonality perspective.
謝謝,也謝謝你的提問。我會用我們所看到的環比趨勢一致的方式來看待。我們預期這種環比趨勢會持續。因此,我認為大致會符合預期,也與你先前從季節性角度所看到的情況一致。
Brian Gil Tanquilut - Senior Equity/Stock Analyst
Brian Gil Tanquilut - Senior Equity/Stock Analyst
Okay. Got it. And then Chris, as I think about some of these new efforts in dental health parity. How are you thinking -- if those stuff which are successful, how do you think that will flow through like operationally or coverage-wise to Acadia?
好的。了解。接著 Chris,當我思考這些在心理健康同等(parity)方面的新舉措時,你們怎麼看——如果這些措施成功,從營運或保障範圍的角度,會如何傳導到 Acadia?
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Yes, it's a great question and 1 that we're still trying to analyze. I mean, you're probably referring to the Biden administration's recent efforts here to ensure that they're going to put out these proposed rules that impact how payers demonstrate mental health parity to federal regulators. And I think the way that will show up for payers is still a little bit to be determined. I mean clearly, the Mental Health Parity Act was put place all the way back in 1996.
是的,這是個很好的問題,也是我們仍在分析的一個問題。你的意思可能是指拜登政府近期的努力,確保他們將提出一些擬議規則(proposed rules),影響付款方如何向聯邦監管機構證明其心理健康同等性。我認為這將如何在付款方端呈現,目前仍有待進一步釐清。很明顯,《心理健康同等法》(Mental Health Parity Act)早在 1996 年就已制定。
So this legislation has been around for decades. The question has been around enforcement, which historically has been pretty limited and inconsistent by both federal and state government. So we applaud the focus on this. But in terms of what the downstream impact will be and ultimately how impactful it will be. I think it's just -- it's a little bit early for us to tell. The first public mention of the rule came in on July 10. And we're still waiting on some additional detail in a public comment period after that. So it's something that we're tracking overall could lead to adjustments over time, but we just don't really have much visibility to share at this point.
因此,這項立法已存在數十年。問題一直在於執法(enforcement),而歷史上無論聯邦或州政府的執法都相當有限且不一致。因此,我們樂見對此的關注。但就下游影響以及最終會有多大影響而言,我認為現在判斷仍稍早。該規則首次公開提及是在 7 月 10 日。我們仍在等待更多細節,以及之後的公開意見徵詢期(public comment period)。因此,這是我們正在追蹤的事項,整體而言可能隨時間推移帶來調整,但目前我們確實沒有太多能分享的能見度。
Operator
Operator
This concludes our question-and-answer session. I would like to turn the conference back over to Chris Hunter for any closing remarks.
我們的問答環節到此結束。接下來我想把電話會議交回給 Chris Hunter,請他做結語。
Christopher Howal Hunter - CEO & Director
Christopher Howal Hunter - CEO & Director
Okay. Thank you. Before we end the call, I just want to again thank our committed facility leaders, clinicians and approximately 23,000 dedicated employees across the country who have continued to work tirelessly to meet the needs of our patients in a safe and effective manner. We really have an outstanding platform for growth and value creation and the momentum in the business right now reinforces our confidence in the future and the work that you all do every day. Thank you all for being with us this morning and for your interest in Acadia. And if you all have any questions at all, please do not hesitate to contact us directly into follow-up. Have a great day, everyone.
好的。謝謝。在結束本次電話會議之前,我想再次感謝我們敬業的機構領導者、臨床人員,以及全國約 23,000 名盡心投入的員工,他們持續不懈地工作,以安全且有效的方式滿足病患需求。我們確實擁有一個卓越的成長與價值創造平台,而目前業務動能也強化了我們對未來的信心,以及你們每天所做的工作。感謝各位今天早上與我們同在,也感謝你們對 Acadia 的關注。若各位還有任何問題,請務必在會後直接與我們聯繫跟進。祝大家有美好的一天。
Operator
Operator
The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.
本次電話會議已結束。感謝各位參加今天的簡報。您現在可以掛線。